Is my estrone‑glucuronide (E1G) level of 43.8 µg on cycle day 20 (seven days after the LH surge) appropriate for early pregnancy while I am receiving progesterone supplementation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

E1G Level Assessment at 7 Days Post-Peak on Progesterone Supplementation

Your E1G level of 43.8 µg/mL on cycle day 20 (7 days post-LH peak) is not directly interpretable for early pregnancy assessment, as E1G monitoring is designed to track ovulation timing rather than confirm or evaluate early pregnancy viability.

Understanding E1G in the Menstrual Cycle Context

E1G (estrone-3-glucuronide) is a urinary metabolite that reflects follicular estrogen production and peaks just before ovulation, then declines significantly in the luteal phase. 1, 2

  • Your pre-ovulatory E1G peaked appropriately at 288.2 µg/mL on CD13, coinciding with your LH surge of 45, which indicates normal follicular development 1, 3
  • The subsequent decline to 197.8 on CD14, 133.7 on CD15, and 43.8 on CD20 represents the expected post-ovulatory pattern 1, 2
  • E1G typically shows a 5-7 fold increase from baseline to peak, then returns toward baseline levels in the luteal phase 1

Why E1G Is Not Used for Early Pregnancy Assessment

E1G monitoring serves to identify the fertile window and confirm ovulation occurred, but it does not provide information about pregnancy establishment or viability. 2

  • E1G reflects ovarian follicular activity, not corpus luteum function or early placental hormone production 1, 2
  • The decline you're seeing from peak to CD20 is physiologically normal for the luteal phase, regardless of whether conception occurred 1, 3
  • Individual E1G patterns vary significantly between women and between cycles in the same woman, with 77% of normal ovulatory cycles differing from mean population curves 3

The Relevant Hormone for Luteal Phase Assessment

PDG (pregnanediol-3-glucuronide), not E1G, is the appropriate urinary marker for evaluating luteal phase adequacy and potential early pregnancy. 4, 2, 5

  • Your PDG rose from 3.1 µg/mL at peak (CD13) to 4.7 on CD14, confirming ovulation occurred 4, 5
  • However, your PDG then dropped to 2.1 on CD15, which is concerning as it fell below your baseline of 3.2 4
  • Your CD20 PDG of 20 µg/mL while on progesterone supplementation reflects exogenous progesterone administration rather than endogenous corpus luteum function 4, 2
  • For natural cycles, PDG should show a sustained 7-fold increase from baseline to luteal phase, and three consecutive readings above 5 µg/mL confirm ovulation with 100% specificity 4

Critical Clinical Concern

The drop in your PDG to 2.1 on CD15 (below your baseline) suggests inadequate corpus luteum function, which is why you are appropriately receiving progesterone supplementation. 4, 2

  • This pattern indicates your corpus luteum may not be producing sufficient progesterone to support early pregnancy without supplementation 2
  • The exogenous progesterone you're taking is masking your endogenous PDG production, making it impossible to assess natural luteal function while on supplementation 4

What Actually Matters for Early Pregnancy

If you are attempting to conceive or suspect early pregnancy, serum beta-hCG testing is the definitive assessment, not urinary E1G levels.

  • E1G provides no information about implantation success or pregnancy viability 2
  • Your progesterone supplementation is appropriate given your luteal phase deficiency pattern 4
  • Continue progesterone supplementation as prescribed until pregnancy can be confirmed or ruled out with serum beta-hCG testing

Common Pitfall to Avoid

Do not attempt to use E1G levels to assess pregnancy status or luteal phase adequacy—this is a misapplication of the hormone marker. 1, 2, 3

  • E1G is solely for identifying the fertile window and confirming ovulation timing 2
  • PDG (when not on supplementation) or serum progesterone are the appropriate markers for luteal function 4, 5
  • Once on exogenous progesterone, urinary PDG measurements no longer reflect endogenous production 4

References

Related Questions

Does a rise in estrone glucuronide (E1G) 12 days after the initial evening luteinizing hormone (LH) surge indicate early pregnancy in a female of reproductive age with a history of progesterone supplementation?
Why did my reproductive endocrinologist advise intercourse a day after the urinary pregnanediol-3-glucuronide rise when I already had sex 2-3 days before ovulation and am taking 200 mg progesterone daily from cycle day 15?
I experienced a peak luteinizing hormone (LH) surge and elevated estradiol (E1G) on cycle day 13‑14, but pregnanediol‑glucuronide (PDG) stayed low; did I ovulate, when should I begin progesterone for luteal support, and how long would the oocyte have remained viable?
Does estrone (e1g) level increase 7-10 days post peak in the luteal phase in a female patient of reproductive age, and if so, how much does it rise above baseline levels?
I am on cycle day 14 with an LH peak of 45 IU, estrone‑3‑glucuronide peak, PDG rise to 4.7 µg/mL, and a brief pelvic pressure at 5:50 pm; did I ovulate, when did it occur, when should I start progesterone for luteal‑phase insufficiency, and how long is the oocyte viable after ovulation?
What are the recommended screening and treatment strategies for depression and cognitive impairment in older adults with Parkinson disease?
What is the typical diffusion distance of submucosal carbon‑black ink after a colonic tattoo and how can excessive spread be minimized?
What are the clinical implications of a pathogenic RTEL1 (Regulator of Telomere Elongation Helicase 1) mutation and what evaluations and monitoring should be performed for affected individuals?
In a female patient with alcohol use disorder who is currently on naltrexone but whose liver status is unknown, should I continue the medication?
How should I treat a urinary tract infection in an elderly patient, accounting for renal function and possible complications such as catheter use or multidrug‑resistant organisms?
Is low‑dose aspirin (81 mg) sufficient for deep‑vein thrombosis prophylaxis in a non‑weight‑bearing patient after surgical fixation of a left tibial plateau fracture?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question